New Study Adds Vytorin Woes For Merck, Schering

Law360, New York (July 22, 2008, 12:00 AM EDT) -- Merck & Co. and Schering-Plough Corp. are facing an increasingly uphill battle to ward off concerns over their jointly marketed cholesterol treatment Vytorin, with a new study reportedly showing that the blockbuster drug is no more effective than a placebo in treating patients with serious heart conditions.

The results of the study, announced Monday by a team of European researchers, found that Vytorin did not prevent complications from aortic stenosis, a condition in which blood flow to the heart is blocked, leading to congestive heart failure...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.